Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

Clinical and Translational Oncology

Volumn 14, Issue 9, 2012, Pages 689-697

  Gómez Martin, Carlos ^a   Sánchez, Antonio ^b   Irigoyen, Antonio ^c   Llorente, Beatriz ^d   Pérez, Begoña ^e   Serrano, Raquel ^f   Safont, Ma José ^g   Falcó, Esther ^h   Lacasta, Adelaida ⁱ   Reboredo, Margarita ^j   Aparicio, Jorge ^k   Dueñas, Rosario ^l   Muñoz, Marta Llanos ^m   Regueiro, Pilar ⁿ   Sanchez Viñes, Elena ⁿ   López, Rafael López ^o  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL SON LLÀTZER   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j HOSPITAL JUAN CANALEJO   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l Hospital of Jaen   (Spain)

^m HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁿ AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^o HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Capecitabine stomach neoplasms; Fluorouracil; Foot dermatoses chemically induced; Hand dermatoses chemically induced; Neoplasm metastasis

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED STOMACH CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CARDIOPULMONARY INSUFFICIENCY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; MALE; METASTATIC STOMACH CANCER; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84871221328     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0858-3     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917
2. Cabanes A, Perez-Gomez B, Aragones N, Pollan M, Lopez-Abente G (2009) La situación del cáncer en España, 1975-2006. INE-Madrid
3. Altekruse SF, Kosary CL, Krapcho M et al (2011) SEER cancer statistics review, 1975-2007, National Cancer Institute. Bethesda, MD. http://seer.cancer. gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
4. Hendlisz A, Bleiberg H (1995) Diagnosis and treatment of gastric cancer. Drugs 49(5):711-720
5. Schipper DL, Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7(2):137-149
6. Lacave AJ, Baron FJ, Anton LM et al (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2(10):751-754
7. Kim NK, Park YS, Heo DS et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71(12):3813-3818
8. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1):261-267
9. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluoro-uracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991-4997
10. Hong YS, Song SY, Lee SI et al (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15(9):1344-1347
11. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T (2003) A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64(3):232-236
12. Sakamoto J, Chin K, Kondo K et al (2006) Phase II study of a 4-week cape-citabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17(2):231-236
13. Kim TW, Kang YK, Ahn JH et al (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13(12):1893-1898
14. Lee J, Im YH, Cho EY et al (2008) A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 62(1):77-84
15. Kang YK, Ryu MH, Yoo C et al (2011) Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 67(6):1435-1443
16. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36-46
17. Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20(4):666-673
18. National Institute for Health and Clinical Excellence (2010) Capecitabine for the treatment of advanced gastric cancer. NICE technology appraisal guidance 191 www.nice.org.uk/guidance/TA191. Accessed 19 Jan 2011
19. Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodyses-thesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11(3):238-246
20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205-216
21. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colo-rectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097-4106
22. Nagore E, Insa A, Sanmartin O (2000) Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1(4):225-234
23. Abushullaih S, Saad ED, Munsell M, Hoff PM (2002) Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20(1):3-10
24. Capecitabine-SPC (2010) Xeloda (capecitabine)-Roche Pharma AG. Summary of Product Characteristics
25. Oxaliplatin-SPC (2010) Oxaliplatin. Summary of Product Characteristics
26. Epirubicin-SPC (2010) Epirubicin. Summary of Product Characteristics
27. Martinez Amores B, Alsina M, Jiménez E et al (2011) Observational transversal study to relate functional status and age with the doublet or triplet chemotherapy based on capecitabine in advanced gastric cancer patients. J Clin Oncol 29: (suppl 4), abstract 59